Immusmol
Loic Cerf serves as the Chief Operating Officer at both Explicyte and ImmuSmol since March 2016, demonstrating expertise in operational leadership within the biotechnology sector. Prior to these roles, Loic held the position of Global Project Manager at Fluofarma from 2006 to December 2015, specializing in High Content Screening and Drug Discovery. Educational credentials include a Specialized Master in Management and Business Intelligence in Biotechnology from TBS Education (2004-2005) and a Research Master in Biochemistry and Molecular Biology from Université de Bordeaux (2003-2004).
This person is not in any teams
Immusmol
Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.